Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re‐uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects. In a review of the pharmacologic literature we showed that antidepressant exposure might...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of clinical pharmacology 2012-01, Vol.73 (1), p.126-134
Hauptverfasser: Nijenhuis, Cynthia M., ter Horst, Peter G. J., van Rein, Nienke, Wilffert, Bob, de Jong‐van den Berg, Lolkje T. W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 134
container_issue 1
container_start_page 126
container_title British journal of clinical pharmacology
container_volume 73
creator Nijenhuis, Cynthia M.
ter Horst, Peter G. J.
van Rein, Nienke
Wilffert, Bob
de Jong‐van den Berg, Lolkje T. W.
description WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects. In a review of the pharmacologic literature we showed that antidepressant exposure might disturb the development of the enteric nervous system. WHAT THIS STUDY ADDS • In utero exposure to selective serotonin re‐uptake inhibitors (SSRIs) in the second and third trimester or to tricyclic antidepressants (TCAs) in the first trimester leads to a significant increase in laxative use compared with non‐exposed children. SSRI exposure was not associated with significant increased antidiarrhoeal medication use, but TCA exposure was. AIMS Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects. METHODS The pharmacy prescription database IADB.nl was used for a cohort study in which laxative and antidiarrhoeal medication use in children after in utero exposure to antidepressants (TCA, SSRI, fluoxetine or paroxetine exposed) was compared with no antidepressant exposure. Laxatives and antidiarrhoeal medication use were applied as a proxy for constipation and diarrhoea respectively, which may be associated with disturbed enteric nervous system (ENS) development. RESULTS Children exposed in utero to SSRIs (mainly fluoxetine and paroxetine) in the second and third trimester or to TCAs in the first trimester, more often received laxatives. Combined exposure to TCAs and SSRIs in pregnancy was associated with a 10‐fold increase in laxative use. In utero exposure to SSRIs is not associated with antidiarrhoeal medication use compared with non‐exposed children. In contrast, antidiarrhoeal medication use was significantly higher in children exposed to TCAs anytime in pregnancy. CONCLUSIONS The increased laxative use after second and third trimester exposure to SSRIs might be explained through the inhibitory effect of the serotonin re‐uptake transporter (SERT) and because of selectivity for the 5‐HT2B receptor which affects the ENS. TCA exposure during the first trimester leads to increased laxative use probably through inhibition of the norepinephrine transporter (NET). Exposure of TCAs anytime in pregnancy leads to increase diarrhoeal use possibly through down‐regulation of α2‐adrenoceptors or up‐regulation of the pore forming α1c subunit.
doi_str_mv 10.1111/j.1365-2125.2011.04081.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3248262</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1221144647</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5361-13302a4c6b833dbea26ac2962211a0f58092655072c8e4934ba5f7eb7fe703553</originalsourceid><addsrcrecordid>eNqNUcuO1DAQjBCIHRZ-AfmCxGWCH3EeSCAtw1NaiT0sZ8txOjsekji4nWHmxifwN_wPX4KzMwxww5cuuaury64kIYymLJ5nm5SJXC454zLllLGUZrRk6e5Osjg17iYLKmi-lFyys-QB4oZSJlgu7ydnnJVZWVV0kfx4bTFMvoaGNLCFzo09DIG4loQ1kAjBW0MG8Fs3IcE9BuiJbuM1sQOZYnUEdqPDycM8hdCBCXYLEXkX3BBZHn5--z6NQX-GOLS2tQ3OI9FDQ0JU35surtBDsA2MHhAjxJRcaR8If06uAYMdbm79rPejixUBHyb3Wt0hPDrW8-TT2zfXq_fLy4_vPqwuLpdGipwtmRCU68zkdSlEU4PmuTa8yjlnTNNWlrTiuZS04KaErBJZrWVbQF20UFAhpThPXh50x6nuoTHxR7zu1Ohtr_1eOW3Vv53BrtWN2yrBs5LnPAo8PQp492WKb1G9RQNdpweIX6rYbCXL8qyI1PJANd4hemhPaxhVc-5qo-Z41RyvmnNXt7mrXRx9_LfN0-DvoCPhyZGg0eiu9XowFv_wJK-44LPdFwfeV9vB_r8NqFerqxmJXz-Fz1g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1221144647</pqid></control><display><type>article</type><title>Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re‐uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Nijenhuis, Cynthia M. ; ter Horst, Peter G. J. ; van Rein, Nienke ; Wilffert, Bob ; de Jong‐van den Berg, Lolkje T. W.</creator><creatorcontrib>Nijenhuis, Cynthia M. ; ter Horst, Peter G. J. ; van Rein, Nienke ; Wilffert, Bob ; de Jong‐van den Berg, Lolkje T. W.</creatorcontrib><description>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects. In a review of the pharmacologic literature we showed that antidepressant exposure might disturb the development of the enteric nervous system. WHAT THIS STUDY ADDS • In utero exposure to selective serotonin re‐uptake inhibitors (SSRIs) in the second and third trimester or to tricyclic antidepressants (TCAs) in the first trimester leads to a significant increase in laxative use compared with non‐exposed children. SSRI exposure was not associated with significant increased antidiarrhoeal medication use, but TCA exposure was. AIMS Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects. METHODS The pharmacy prescription database IADB.nl was used for a cohort study in which laxative and antidiarrhoeal medication use in children after in utero exposure to antidepressants (TCA, SSRI, fluoxetine or paroxetine exposed) was compared with no antidepressant exposure. Laxatives and antidiarrhoeal medication use were applied as a proxy for constipation and diarrhoea respectively, which may be associated with disturbed enteric nervous system (ENS) development. RESULTS Children exposed in utero to SSRIs (mainly fluoxetine and paroxetine) in the second and third trimester or to TCAs in the first trimester, more often received laxatives. Combined exposure to TCAs and SSRIs in pregnancy was associated with a 10‐fold increase in laxative use. In utero exposure to SSRIs is not associated with antidiarrhoeal medication use compared with non‐exposed children. In contrast, antidiarrhoeal medication use was significantly higher in children exposed to TCAs anytime in pregnancy. CONCLUSIONS The increased laxative use after second and third trimester exposure to SSRIs might be explained through the inhibitory effect of the serotonin re‐uptake transporter (SERT) and because of selectivity for the 5‐HT2B receptor which affects the ENS. TCA exposure during the first trimester leads to increased laxative use probably through inhibition of the norepinephrine transporter (NET). Exposure of TCAs anytime in pregnancy leads to increase diarrhoeal use possibly through down‐regulation of α2‐adrenoceptors or up‐regulation of the pore forming α1c subunit.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/j.1365-2125.2011.04081.x</identifier><identifier>PMID: 21848990</identifier><identifier>CODEN: BCPHBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Abnormalities, Drug-Induced - etiology ; alpha 2-Adrenergic receptors ; Antidepressants ; Antidepressive Agents, Tricyclic - adverse effects ; Biological and medical sciences ; Children ; Cohort Studies ; cohort study ; Constipation ; Depressive Disorder - drug therapy ; Diarrhea ; Enteric nervous system ; Enteric Nervous System - drug effects ; Female ; Fluoxetine ; Humans ; Intrauterine exposure ; Laxatives ; Medical sciences ; Norepinephrine Plasma Membrane Transport Proteins - drug effects ; Norepinephrine transporter ; paroxetine ; Pharmacoepidemiology ; Pharmacology. Drug treatments ; Pores ; Pregnancy ; Prenatal Exposure Delayed Effects - chemically induced ; Reviews ; selective serotonin re‐uptake inhibitor ; serotonin re‐uptake transporter ; Serotonin S2 receptors ; Serotonin transporter ; Serotonin uptake inhibitors ; Serotonin Uptake Inhibitors - adverse effects ; Teratogenicity ; Time Factors ; Tricyclic antidepressants</subject><ispartof>British journal of clinical pharmacology, 2012-01, Vol.73 (1), p.126-134</ispartof><rights>2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society</rights><rights>2015 INIST-CNRS</rights><rights>2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.</rights><rights>Copyright © 2012 The British Pharmacological Society 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5361-13302a4c6b833dbea26ac2962211a0f58092655072c8e4934ba5f7eb7fe703553</citedby><cites>FETCH-LOGICAL-c5361-13302a4c6b833dbea26ac2962211a0f58092655072c8e4934ba5f7eb7fe703553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2125.2011.04081.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2125.2011.04081.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,4010,27900,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25292322$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21848990$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nijenhuis, Cynthia M.</creatorcontrib><creatorcontrib>ter Horst, Peter G. J.</creatorcontrib><creatorcontrib>van Rein, Nienke</creatorcontrib><creatorcontrib>Wilffert, Bob</creatorcontrib><creatorcontrib>de Jong‐van den Berg, Lolkje T. W.</creatorcontrib><title>Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re‐uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects. In a review of the pharmacologic literature we showed that antidepressant exposure might disturb the development of the enteric nervous system. WHAT THIS STUDY ADDS • In utero exposure to selective serotonin re‐uptake inhibitors (SSRIs) in the second and third trimester or to tricyclic antidepressants (TCAs) in the first trimester leads to a significant increase in laxative use compared with non‐exposed children. SSRI exposure was not associated with significant increased antidiarrhoeal medication use, but TCA exposure was. AIMS Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects. METHODS The pharmacy prescription database IADB.nl was used for a cohort study in which laxative and antidiarrhoeal medication use in children after in utero exposure to antidepressants (TCA, SSRI, fluoxetine or paroxetine exposed) was compared with no antidepressant exposure. Laxatives and antidiarrhoeal medication use were applied as a proxy for constipation and diarrhoea respectively, which may be associated with disturbed enteric nervous system (ENS) development. RESULTS Children exposed in utero to SSRIs (mainly fluoxetine and paroxetine) in the second and third trimester or to TCAs in the first trimester, more often received laxatives. Combined exposure to TCAs and SSRIs in pregnancy was associated with a 10‐fold increase in laxative use. In utero exposure to SSRIs is not associated with antidiarrhoeal medication use compared with non‐exposed children. In contrast, antidiarrhoeal medication use was significantly higher in children exposed to TCAs anytime in pregnancy. CONCLUSIONS The increased laxative use after second and third trimester exposure to SSRIs might be explained through the inhibitory effect of the serotonin re‐uptake transporter (SERT) and because of selectivity for the 5‐HT2B receptor which affects the ENS. TCA exposure during the first trimester leads to increased laxative use probably through inhibition of the norepinephrine transporter (NET). Exposure of TCAs anytime in pregnancy leads to increase diarrhoeal use possibly through down‐regulation of α2‐adrenoceptors or up‐regulation of the pore forming α1c subunit.</description><subject>Abnormalities, Drug-Induced - etiology</subject><subject>alpha 2-Adrenergic receptors</subject><subject>Antidepressants</subject><subject>Antidepressive Agents, Tricyclic - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Children</subject><subject>Cohort Studies</subject><subject>cohort study</subject><subject>Constipation</subject><subject>Depressive Disorder - drug therapy</subject><subject>Diarrhea</subject><subject>Enteric nervous system</subject><subject>Enteric Nervous System - drug effects</subject><subject>Female</subject><subject>Fluoxetine</subject><subject>Humans</subject><subject>Intrauterine exposure</subject><subject>Laxatives</subject><subject>Medical sciences</subject><subject>Norepinephrine Plasma Membrane Transport Proteins - drug effects</subject><subject>Norepinephrine transporter</subject><subject>paroxetine</subject><subject>Pharmacoepidemiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pores</subject><subject>Pregnancy</subject><subject>Prenatal Exposure Delayed Effects - chemically induced</subject><subject>Reviews</subject><subject>selective serotonin re‐uptake inhibitor</subject><subject>serotonin re‐uptake transporter</subject><subject>Serotonin S2 receptors</subject><subject>Serotonin transporter</subject><subject>Serotonin uptake inhibitors</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Teratogenicity</subject><subject>Time Factors</subject><subject>Tricyclic antidepressants</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUcuO1DAQjBCIHRZ-AfmCxGWCH3EeSCAtw1NaiT0sZ8txOjsekji4nWHmxifwN_wPX4KzMwxww5cuuaury64kIYymLJ5nm5SJXC454zLllLGUZrRk6e5Osjg17iYLKmi-lFyys-QB4oZSJlgu7ydnnJVZWVV0kfx4bTFMvoaGNLCFzo09DIG4loQ1kAjBW0MG8Fs3IcE9BuiJbuM1sQOZYnUEdqPDycM8hdCBCXYLEXkX3BBZHn5--z6NQX-GOLS2tQ3OI9FDQ0JU35surtBDsA2MHhAjxJRcaR8If06uAYMdbm79rPejixUBHyb3Wt0hPDrW8-TT2zfXq_fLy4_vPqwuLpdGipwtmRCU68zkdSlEU4PmuTa8yjlnTNNWlrTiuZS04KaErBJZrWVbQF20UFAhpThPXh50x6nuoTHxR7zu1Ohtr_1eOW3Vv53BrtWN2yrBs5LnPAo8PQp492WKb1G9RQNdpweIX6rYbCXL8qyI1PJANd4hemhPaxhVc-5qo-Z41RyvmnNXt7mrXRx9_LfN0-DvoCPhyZGg0eiu9XowFv_wJK-44LPdFwfeV9vB_r8NqFerqxmJXz-Fz1g</recordid><startdate>201201</startdate><enddate>201201</enddate><creator>Nijenhuis, Cynthia M.</creator><creator>ter Horst, Peter G. J.</creator><creator>van Rein, Nienke</creator><creator>Wilffert, Bob</creator><creator>de Jong‐van den Berg, Lolkje T. W.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Blackwell Science Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>201201</creationdate><title>Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re‐uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses</title><author>Nijenhuis, Cynthia M. ; ter Horst, Peter G. J. ; van Rein, Nienke ; Wilffert, Bob ; de Jong‐van den Berg, Lolkje T. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5361-13302a4c6b833dbea26ac2962211a0f58092655072c8e4934ba5f7eb7fe703553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abnormalities, Drug-Induced - etiology</topic><topic>alpha 2-Adrenergic receptors</topic><topic>Antidepressants</topic><topic>Antidepressive Agents, Tricyclic - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Children</topic><topic>Cohort Studies</topic><topic>cohort study</topic><topic>Constipation</topic><topic>Depressive Disorder - drug therapy</topic><topic>Diarrhea</topic><topic>Enteric nervous system</topic><topic>Enteric Nervous System - drug effects</topic><topic>Female</topic><topic>Fluoxetine</topic><topic>Humans</topic><topic>Intrauterine exposure</topic><topic>Laxatives</topic><topic>Medical sciences</topic><topic>Norepinephrine Plasma Membrane Transport Proteins - drug effects</topic><topic>Norepinephrine transporter</topic><topic>paroxetine</topic><topic>Pharmacoepidemiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pores</topic><topic>Pregnancy</topic><topic>Prenatal Exposure Delayed Effects - chemically induced</topic><topic>Reviews</topic><topic>selective serotonin re‐uptake inhibitor</topic><topic>serotonin re‐uptake transporter</topic><topic>Serotonin S2 receptors</topic><topic>Serotonin transporter</topic><topic>Serotonin uptake inhibitors</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Teratogenicity</topic><topic>Time Factors</topic><topic>Tricyclic antidepressants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nijenhuis, Cynthia M.</creatorcontrib><creatorcontrib>ter Horst, Peter G. J.</creatorcontrib><creatorcontrib>van Rein, Nienke</creatorcontrib><creatorcontrib>Wilffert, Bob</creatorcontrib><creatorcontrib>de Jong‐van den Berg, Lolkje T. W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nijenhuis, Cynthia M.</au><au>ter Horst, Peter G. J.</au><au>van Rein, Nienke</au><au>Wilffert, Bob</au><au>de Jong‐van den Berg, Lolkje T. W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re‐uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2012-01</date><risdate>2012</risdate><volume>73</volume><issue>1</issue><spage>126</spage><epage>134</epage><pages>126-134</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><coden>BCPHBM</coden><abstract>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects. In a review of the pharmacologic literature we showed that antidepressant exposure might disturb the development of the enteric nervous system. WHAT THIS STUDY ADDS • In utero exposure to selective serotonin re‐uptake inhibitors (SSRIs) in the second and third trimester or to tricyclic antidepressants (TCAs) in the first trimester leads to a significant increase in laxative use compared with non‐exposed children. SSRI exposure was not associated with significant increased antidiarrhoeal medication use, but TCA exposure was. AIMS Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects. METHODS The pharmacy prescription database IADB.nl was used for a cohort study in which laxative and antidiarrhoeal medication use in children after in utero exposure to antidepressants (TCA, SSRI, fluoxetine or paroxetine exposed) was compared with no antidepressant exposure. Laxatives and antidiarrhoeal medication use were applied as a proxy for constipation and diarrhoea respectively, which may be associated with disturbed enteric nervous system (ENS) development. RESULTS Children exposed in utero to SSRIs (mainly fluoxetine and paroxetine) in the second and third trimester or to TCAs in the first trimester, more often received laxatives. Combined exposure to TCAs and SSRIs in pregnancy was associated with a 10‐fold increase in laxative use. In utero exposure to SSRIs is not associated with antidiarrhoeal medication use compared with non‐exposed children. In contrast, antidiarrhoeal medication use was significantly higher in children exposed to TCAs anytime in pregnancy. CONCLUSIONS The increased laxative use after second and third trimester exposure to SSRIs might be explained through the inhibitory effect of the serotonin re‐uptake transporter (SERT) and because of selectivity for the 5‐HT2B receptor which affects the ENS. TCA exposure during the first trimester leads to increased laxative use probably through inhibition of the norepinephrine transporter (NET). Exposure of TCAs anytime in pregnancy leads to increase diarrhoeal use possibly through down‐regulation of α2‐adrenoceptors or up‐regulation of the pore forming α1c subunit.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21848990</pmid><doi>10.1111/j.1365-2125.2011.04081.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0306-5251
ispartof British journal of clinical pharmacology, 2012-01, Vol.73 (1), p.126-134
issn 0306-5251
1365-2125
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3248262
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Abnormalities, Drug-Induced - etiology
alpha 2-Adrenergic receptors
Antidepressants
Antidepressive Agents, Tricyclic - adverse effects
Biological and medical sciences
Children
Cohort Studies
cohort study
Constipation
Depressive Disorder - drug therapy
Diarrhea
Enteric nervous system
Enteric Nervous System - drug effects
Female
Fluoxetine
Humans
Intrauterine exposure
Laxatives
Medical sciences
Norepinephrine Plasma Membrane Transport Proteins - drug effects
Norepinephrine transporter
paroxetine
Pharmacoepidemiology
Pharmacology. Drug treatments
Pores
Pregnancy
Prenatal Exposure Delayed Effects - chemically induced
Reviews
selective serotonin re‐uptake inhibitor
serotonin re‐uptake transporter
Serotonin S2 receptors
Serotonin transporter
Serotonin uptake inhibitors
Serotonin Uptake Inhibitors - adverse effects
Teratogenicity
Time Factors
Tricyclic antidepressants
title Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re‐uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T12%3A22%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Disturbed%20development%20of%20the%20enteric%20nervous%20system%20after%20in%20utero%20exposure%20of%20selective%20serotonin%20re%E2%80%90uptake%20inhibitors%20and%20tricyclic%20antidepressants.%20Part%202:%20Testing%20the%20hypotheses&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Nijenhuis,%20Cynthia%20M.&rft.date=2012-01&rft.volume=73&rft.issue=1&rft.spage=126&rft.epage=134&rft.pages=126-134&rft.issn=0306-5251&rft.eissn=1365-2125&rft.coden=BCPHBM&rft_id=info:doi/10.1111/j.1365-2125.2011.04081.x&rft_dat=%3Cproquest_pubme%3E1221144647%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1221144647&rft_id=info:pmid/21848990&rfr_iscdi=true